Transforming Treatment of Severe Blood Disorders

learn more »

A Commitment to Serving Patients and Their Families

learn more »

Innovative Science

Global Blood Therapeutics (GBT) is dedicated to discovering, developing, and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders.

GBT440, our lead drug candidate, targets the underlying mechanism of red blood cell sickling, which provides the potential to treat sickle cell disease (SCD) rather than only its symptoms.

more »

Spotlight on GBT440

GBT440 is an oral, once-daily therapy in development for patients with sickle cell disease (SCD).

With a mechanism of action that addresses the fundamental pathology of SCD, GBT440 is being investigated for its potential to ameliorate disease progression and transform the treatment of SCD patients.

 

more »